News | December 03, 2007

Drug-Eluting Stents Improve Patient Outcomes in Routine Practice

December 4, 2007 - In general, drug-eluting stents (DES) achieve better results than bare-metal stents do, U.S. researchers report in the November 20 issue of the Journal of the American College of Cardiology.

"We found that DES, as they are being used in clinical practice in North America, significantly reduce the need for target vessel revascularization compared to bare-metal stents," lead investigator J. Dawn Abbott, M.D., told Reuters Health.

"Importantly," she added, this reduction "was observed in patients with and without complex coronary lesion types."

Dr. Abbott of Rhode Island Hospital, Providence, and colleagues studied data from 2004 for 1460 patients who received at least one DES. These data were compared with earlier records for 1,763 patients who received at least one bare-metal stent.

At one year, the cumulative death and myocardial infarction rate was 7.6 percent in DES patients and 8.7 percent in bare-metal stent patients, a nonsignificant difference. The corresponding rate of target vessel revascularization at one year was 5.0 percent and 9.2 percent (p

In DES patients, the one-year hazard ratio for any repeat vascularization by percutaneous coronary intervention or coronary bypass was 0.38, and the rate of stent thrombosis was 1 percent.

"These improved outcomes," continued Dr. Abbott, "were achieved without any evidence of increased hazard from DES use, as demonstrated by similar one-year rates of death and myocardial infarction, and a very low rate of angiographically confirmed late stent thrombosis."

"While these results certainly confirm the efficacy of DES," she concluded, "we will need longer follow-up to evaluate the incidence of very late stent thrombosis in these patients."

In an accompanying editorial, Franz-Josef Neumann, M.D., Herz-Zentrum, Bad Krozingen, Germany writes that the "mounting evidence on this matter confirms the superior efficacy of DES with respect to the prevention of repeat revascularization and does not suggest inferior safety compared with bare-metal stents."

Ref: J Am Coll Cardiol 2007;50:2029-2038
Source: Reuters Health, December 3, 2007

For more information: www.acc.org


Related Content

News | Stents Drug Eluting

July 2, 2024 — Biotronik announced the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro ...

Home July 02, 2024
Home
News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
Subscribe Now